The Utility of the Myriad myRisk Hereditary Cancer Test
Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.
Clinical Pearls
Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary CancerTMTest.
- MyRisk is a genetic test that looks for mutations in 25 genes that are known to be associated with significantly elevated risk for cancer
- There are eight major cancers the test can detect, including breast cancer, ovarian cancer, melanoma, and endometrial cancer.
- The test allows physicians to increase the rate of detection for individuals that have mutations or who have hereditary cancer syndromes
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
